{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:49:18Z","timestamp":1792464558080,"version":"4.5.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA-22453"],"award-info":[{"award-number":["CA-22453"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jbc.2022.102622","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T23:37:25Z","timestamp":1666222645000},"page":"102622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases"],"prefix":"10.1016","volume":"298","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1917-169X","authenticated-orcid":false,"given":"Pratima","family":"Nangia-Makker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2022.102622_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/14789450.2016.1134327","article-title":"Protein degradation fragments as diagnostic and prognostic biomarkers of connective tissue diseases: understanding the extracellular matrix message and implication for current and future serological biomarkers","volume":"13","author":"Genovese","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.jbc.2022.102622_bib2","first-page":"S88","article-title":"Interleukin-1 in renal fibrosis","volume":"54","author":"Nikolic-Paterson","year":"1996","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.jbc.2022.102622_bib3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2012.04.003","article-title":"Interleukin-6, its role in fibrosing conditions","volume":"23","author":"O'Reilly","year":"2012","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbc.2022.102622_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.28622","article-title":"The secretin\/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-beta1 biliary secretion in mice","volume":"64","author":"Wu","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jbc.2022.102622_bib5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-beta mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jbc.2022.102622_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nri1412","article-title":"Fibrotic disease and the T(H)1\/T(H)2 paradigm","volume":"4","author":"Wynn","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jbc.2022.102622_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/ar.23567","article-title":"Basement membrane type IV collagen and laminin: an overview of their biology and value as fibrosis biomarkers of liver disease","volume":"300","author":"Mak","year":"2017","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.jbc.2022.102622_bib8","first-page":"314","article-title":"Basal lamina scaffold-anatomy and significance for maintenance of orderly tissue structure","volume":"77","author":"Vracko","year":"1974","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jbc.2022.102622_bib9","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/liv.14390","article-title":"Collagen biology and non-invasive biomarkers of liver fibrosis","volume":"40","author":"Karsdal","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.jbc.2022.102622_bib10","doi-asserted-by":"crossref","first-page":"a004978","DOI":"10.1101\/cshperspect.a004978","article-title":"The collagen family","volume":"3","author":"Ricard-Blum","year":"2011","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib11","first-page":"3489","article-title":"Identification of the metastasis-associated, galactoside-binding lectin as a chimeric gene product with homology to an IgE-binding protein","volume":"49","author":"Raz","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib12","first-page":"2173","article-title":"Molecular cloning and chromosomal mapping of a human galactoside-binding protein","volume":"51","author":"Raz","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib13","first-page":"6239","article-title":"The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells","volume":"59","author":"Gong","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib14","doi-asserted-by":"crossref","first-page":"14109","DOI":"10.1021\/bi00251a020","article-title":"Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9","volume":"33","author":"Ochieng","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2022.102622_bib15","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1158\/0008-5472.CAN-07-3233","article-title":"Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers","volume":"67","author":"Nangia-Makker","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib16","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1158\/0008-5472.CAN-08-3224","article-title":"Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study","volume":"68","author":"Balan","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib17","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0304-4165(97)00086-X","article-title":"Modulation of the biological functions of galectin-3 by matrix metalloproteinases","volume":"1379","author":"Ochieng","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2022.102622_bib18","doi-asserted-by":"crossref","first-page":"17845","DOI":"10.1074\/jbc.M117.802793","article-title":"The intrinsically disordered N-terminal domain of galectin-3 dynamically mediates multisite self-association of the protein through fuzzy interactions","volume":"292","author":"Lin","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/35055582","article-title":"Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation","volume":"409","author":"Demetriou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2022.102622_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/glycob\/cwu111","article-title":"Galectin-3: an emerging all-out player in metabolic disorders and their complications","volume":"25","author":"Pugliese","year":"2015","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2022.102622_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/biom10030389","article-title":"Galectin-3 as a next-generation biomarker for detecting early stage of various diseases","volume":"10","author":"Hara","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.jbc.2022.102622_bib22","first-page":"A57","article-title":"Ex\u00a0vivo studies of the gal-3-fibrosome hypothesis in IPF and non-fibrotic control lung tissue and myofibroblasts.","volume":"74","author":"Miah","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2022.102622_bib23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1358\/dnp.2007.20.7.1183933","article-title":"The role of galectin-3 in promotion of the inflammatory response","volume":"20","author":"Liu","year":"2007","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.jbc.2022.102622_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1089\/ars.2019.7753","article-title":"Galectin-3: a harbinger of reactive oxygen species, fibrosis, and inflammation in pulmonary arterial hypertension","volume":"31","author":"Fulton","year":"2019","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.jbc.2022.102622_bib25","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","article-title":"Regulation of alternative macrophage activation by galectin-3","volume":"180","author":"MacKinnon","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2022.102622_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1164\/rccm.201106-0965OC","article-title":"Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3","volume":"185","author":"Mackinnon","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbc.2022.102622_bib27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4049\/jimmunol.168.4.1813","article-title":"Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia","volume":"168","author":"Sato","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2022.102622_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1023\/A:1018554124545","article-title":"Macrophage surface glycoproteins binding to galectin-3 (Mac-2-antigen)","volume":"14","author":"Dong","year":"1997","journal-title":"Glycoconj J."},{"key":"10.1016\/j.jbc.2022.102622_bib29","doi-asserted-by":"crossref","first-page":"105881","DOI":"10.1016\/j.biocel.2020.105881","article-title":"The therapeutic potential of galectin-3 inhibition in fibrotic disease","volume":"130","author":"Slack","year":"2021","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/hep.1840140519","article-title":"The role of capillarization in hepatic failure: studies in carbon tetrachloride-induced cirrhosis","volume":"14","author":"Martinez-Hernandez","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jbc.2022.102622_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2013.08.015","article-title":"Different collagen types show distinct rates of increase from early to late stages of hepatitis C-related liver fibrosis","volume":"45","author":"Chen","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jbc.2022.102622_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0174-173X(82)80031-9","article-title":"The extracellular matrix of the liver","volume":"2","author":"Rojkind","year":"1982","journal-title":"Coll. Relat. Res."},{"key":"10.1016\/j.jbc.2022.102622_bib33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3109\/00365529209000114","article-title":"Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen","volume":"27","author":"Ueno","year":"1992","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.jbc.2022.102622_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF02389524","article-title":"Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide","volume":"31","author":"Hirayama","year":"1996","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.jbc.2022.102622_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0168-8278(96)80023-7","article-title":"Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease","volume":"24","author":"Murawaki","year":"1996","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jbc.2022.102622_bib36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3748\/wjg.v11.i2.255","article-title":"Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sakugawa","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jbc.2022.102622_bib37","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00535-007-2014-3","article-title":"Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage","volume":"42","author":"Yoneda","year":"2007","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.jbc.2022.102622_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0168-8278(90)90067-2","article-title":"Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propeptide of procollagen type III (PIIIP) in chronic liver disease","volume":"10","author":"Hayasaka","year":"1990","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jbc.2022.102622_bib39","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.1840110503","article-title":"Endothelial cell transformation in primary biliary cirrhosis: a morphological and biochemical study","volume":"11","author":"Babbs","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jbc.2022.102622_bib40","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jbc.2022.102622_bib41","doi-asserted-by":"crossref","first-page":"e0202393","DOI":"10.1371\/journal.pone.0202393","article-title":"Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease","volume":"13","author":"Peleg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib42","doi-asserted-by":"crossref","first-page":"e0137302","DOI":"10.1371\/journal.pone.0137302","article-title":"Markers of collagen remodeling detect clinically significant fibrosis in chronic hepatitis C patients","volume":"10","author":"Nielsen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1530-0277.1992.tb01388.x","article-title":"Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: relationship to liver histology","volume":"16","author":"Trinchet","year":"1992","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.jbc.2022.102622_bib44","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbc.2022.102622_bib45","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.jbc.2022.102622_bib46","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.jbc.2022.102622_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.bjp.0707395","article-title":"Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors","volume":"153","author":"Negre-Salvayre","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jbc.2022.102622_bib48","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.2005.032391","article-title":"Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease","volume":"60","author":"Butscheid","year":"2007","journal-title":"J.\u00a0Clin. Pathol."},{"key":"10.1016\/j.jbc.2022.102622_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","article-title":"Cardiac fibrosis - a short review of causes and therapeutic strategies","volume":"146","author":"Hinderer","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jbc.2022.102622_bib50","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-2828(88)80059-2","article-title":"Collagen chain mRNAs in isolated heart cells from young and adult rats","volume":"20","author":"Eghbali","year":"1988","journal-title":"J.\u00a0Mol. Cell Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0022-2828(89)91498-3","article-title":"Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization","volume":"21","author":"Eghbali","year":"1989","journal-title":"J.\u00a0Mol. Cell Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib52","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1083\/jcb.102.3.703","article-title":"Molecular assembly, secretion, and matrix deposition of type VI collagen","volume":"102","author":"Engvall","year":"1986","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib53","doi-asserted-by":"crossref","first-page":"107150","DOI":"10.1016\/j.carpath.2019.107150","article-title":"Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy","volume":"43","author":"Yang","year":"2019","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.jbc.2022.102622_bib54","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2018-313182","article-title":"Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure","volume":"105","author":"Ferreira","year":"2019","journal-title":"Heart"},{"key":"10.1016\/j.jbc.2022.102622_bib55","article-title":"Relations between markers of cardiac remodelling and left ventricular collagen in an isoproterenol-induced heart damage model","volume":"70","author":"Adamcova","year":"2019","journal-title":"J.\u00a0Physiol. Pharmacol."},{"key":"10.1016\/j.jbc.2022.102622_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejim.2006.09.014","article-title":"Propeptide of procollagen type I (PIP) and outcomes in decompensated heart failure","volume":"18","author":"Ruiz-Ruiz","year":"2007","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib57","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1074\/jbc.M105601200","article-title":"Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3","volume":"277","author":"Colige","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of sacubitril\/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib59","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1159\/000489653","article-title":"Renal denervation effects on myocardial fibrosis and ventricular arrhythmias in rats with ischemic cardiomyopathy","volume":"46","author":"Zhang","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.jbc.2022.102622_bib60","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0002-9149(99)80686-9","article-title":"Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis","volume":"75","author":"Klappacher","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.14336\/AD.2020.0604","article-title":"Roles of biomarkers in myocardial fibrosis","volume":"11","author":"Ding","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.jbc.2022.102622_bib62","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/01.CIR.0000090687.97972.10","article-title":"Myocardial collagen turnover in hypertrophic cardiomyopathy","volume":"108","author":"Lombardi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jbc.2022.102622_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/1354750X.2015.1118539","article-title":"Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis","volume":"21","author":"Morine","year":"2016","journal-title":"Biomarkers"},{"key":"10.1016\/j.jbc.2022.102622_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jacc.2008.03.045","article-title":"Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover","volume":"52","author":"Kallergis","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib65","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2010.04.034","article-title":"The prognostic value of circulating markers of collagen turnover after acute myocardial infarction","volume":"150","author":"Manhenke","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib66","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ehf2.12360","article-title":"Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression","volume":"5","author":"Nagao","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.jbc.2022.102622_bib67","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American heart association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jbc.2022.102622_bib68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","article-title":"Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials","volume":"167","author":"Meijers","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jbc.2022.102622_bib69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.amjcard.2016.09.019","article-title":"Meta-analysis of the usefulness of plasma galectin-3 to predict the risk of mortality in patients with heart failure and in the general population","volume":"119","author":"Imran","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10741-019-09858-2","article-title":"Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis","volume":"25","author":"Chen","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.jbc.2022.102622_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/CIRCHEARTFAILURE.111.963637","article-title":"Galectin-3 in ambulatory patients with heart failure: results from the HF-action study","volume":"5","author":"Felker","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.jbc.2022.102622_bib72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ejhf.749","article-title":"A\u00a0multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial","volume":"19","author":"Demissei","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.jbc.2022.102622_bib73","doi-asserted-by":"crossref","first-page":"e014385","DOI":"10.1161\/JAHA.119.014385","article-title":"Association of cardiac biomarkers with the Kansas city cardiomyopathy questionnaire in patients with chronic kidney disease without heart failure","volume":"9","author":"Tummalapalli","year":"2020","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.jbc.2022.102622_bib74","doi-asserted-by":"crossref","first-page":"9232","DOI":"10.3390\/ijms21239232","article-title":"Galectin-3 in cardiovascular diseases","volume":"21","author":"Blanda","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2022.102622_bib75","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/039463201102400409","article-title":"Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome","volume":"24","author":"Falcone","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.jbc.2022.102622_bib76","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/0003319718780772","article-title":"Plasma galectin-3 and sonographic measures of carotid atherosclerosis in the atherosclerosis risk in communities study","volume":"70","author":"Oyenuga","year":"2019","journal-title":"Angiology"},{"key":"10.1016\/j.jbc.2022.102622_bib77","first-page":"289","article-title":"Galectin-3 and Lp(a) plasma concentrations and advanced carotid atherosclerotic plaques: correlation with plaque presence and features","volume":"43","author":"Ciaccio","year":"2019","journal-title":"Biochim. Cli."},{"key":"10.1016\/j.jbc.2022.102622_bib78","first-page":"5284728","article-title":"Galectin-3 is a potential mediator for atherosclerosis","volume":"2020","author":"Gao","year":"2020","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.jbc.2022.102622_bib79","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jbc.2022.102622_bib80","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.bbamcr.2014.12.001","article-title":"Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression","volume":"1853","author":"Song","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2022.102622_bib81","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ehf2.12359","article-title":"Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study","volume":"6","author":"Ferreira","year":"2019","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.jbc.2022.102622_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2019.04.049","article-title":"Negative risk markers for cardiovascular events in the elderly","volume":"74","author":"Mortensen","year":"2019","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.jbc.2022.102622_bib83","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.114.304964","article-title":"Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease","volume":"35","author":"Maiolino","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib84","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/jim-2015-000041","article-title":"Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis?","volume":"64","author":"Aksan","year":"2016","journal-title":"J.\u00a0Investig. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib85","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/jcm9061640","article-title":"Galectin-3 as the prognostic factor of adverse cardiovascular events in long-term follow up in patients after myocardial infarction-A pilot study","volume":"9","author":"Swiecki","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib86","doi-asserted-by":"crossref","first-page":"109752","DOI":"10.18632\/oncotarget.18211","article-title":"Serum Galectin-3 level, not Galectin-1, is associated with the clinical feature and outcome in patients with acute ischemic stroke","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbc.2022.102622_bib87","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000443022","article-title":"High plasma levels of galectin-3 are associated with increased risk for stroke after carotid endarterectomy","volume":"41","author":"Edsfeldt","year":"2016","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.jbc.2022.102622_bib88","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3390\/ijms18050973","article-title":"Galectin-3 in peripheral artery disease. Relationships with markers of oxidative stress and inflammation","volume":"18","author":"Fort-Gallifa","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2022.102622_bib89","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.59.2.181","article-title":"Pulmonary hypertension in rats living under compressed air conditions","volume":"59","author":"Bennett","year":"1934","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib90","first-page":"657","article-title":"The connective tissue of lung","volume":"112","author":"Hance","year":"1975","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.jbc.2022.102622_bib91","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1172\/JCI108420","article-title":"Collagen polymorphism in idiopathic chronic pulmonary fibrosis","volume":"57","author":"Seyer","year":"1976","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.jbc.2022.102622_bib92","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/thx.36.9.645","article-title":"Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease","volume":"36","author":"Bateman","year":"1981","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2022.102622_bib93","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0046-8177(80)80031-1","article-title":"Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis","volume":"11","author":"Madri","year":"1980","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.jbc.2022.102622_bib94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/thx.41.5.355","article-title":"Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis","volume":"41","author":"Selman","year":"1986","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2022.102622_bib95","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1164\/ajrccm.154.6.8970376","article-title":"Proteoglycan deposition in pulmonary fibrosis","volume":"154","author":"Bensadoun","year":"1996","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbc.2022.102622_bib96","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1164\/ajrccm.162.4.9912011","article-title":"Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects","volume":"162","author":"Ebihara","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbc.2022.102622_bib97","doi-asserted-by":"crossref","first-page":"L1327","DOI":"10.1152\/ajplung.2001.280.6.L1327","article-title":"Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung","volume":"280","author":"Kolb","year":"2001","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.jbc.2022.102622_bib98","doi-asserted-by":"crossref","first-page":"e84934","DOI":"10.1371\/journal.pone.0084934","article-title":"MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis\u2013validation of two novel biomarker assays","volume":"8","author":"Sand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib99","first-page":"130","article-title":"Differential expression of collagens type I and type IV in lymphangiogenesis during the angiogenic process associated with bleomycin-induced pulmonary fibrosis in rat","volume":"38","author":"Teles-Grilo","year":"2005","journal-title":"Lymphology"},{"key":"10.1016\/j.jbc.2022.102622_bib100","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/thx.44.2.126","article-title":"Hyaluronan and type III procollagen peptide concentrations in bronchoalveolar lavage fluid in idiopathic pulmonary fibrosis","volume":"44","author":"Bjermer","year":"1989","journal-title":"Thorax"},{"key":"10.1016\/j.jbc.2022.102622_bib101","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1369\/jhc.5A6835.2006","article-title":"Active remodeling in idiopathic interstitial pneumonias: evaluation of collagen types XII and XIV","volume":"54","author":"Tzortzaki","year":"2006","journal-title":"J.\u00a0Histochem. Cytochem."},{"key":"10.1016\/j.jbc.2022.102622_bib102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4137\/BMI.S9415","article-title":"Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis","volume":"7","author":"Leeming","year":"2012","journal-title":"Biomark Insights"},{"key":"10.1016\/j.jbc.2022.102622_bib103","doi-asserted-by":"crossref","first-page":"e6617","DOI":"10.1097\/MD.0000000000006617","article-title":"Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease","volume":"96","author":"Su","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbc.2022.102622_bib104","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1164\/ajrccm\/146.3.701","article-title":"Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis","volume":"146","author":"Low","year":"1992","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.jbc.2022.102622_bib105","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/1756-185X.13804","article-title":"Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis","volume":"23","author":"Kubo","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jbc.2022.102622_bib106","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","article-title":"Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study","volume":"3","author":"Jenkins","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib107","doi-asserted-by":"crossref","first-page":"20753","DOI":"10.1073\/pnas.2004281117","article-title":"Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP\/EP300","volume":"117","author":"Williams","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102622_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125185","article-title":"Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis","volume":"4","author":"Herrera","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbc.2022.102622_bib109","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.actbio.2016.12.023","article-title":"Defining the hierarchical organisation of collagen VI microfibrils at nanometre to micrometre length scales","volume":"52","author":"Godwin","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jbc.2022.102622_bib110","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1164\/ajrccm.151.6.7767545","article-title":"Increased expression of type VI collagen in lung fibrosis","volume":"151","author":"Specks","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbc.2022.102622_bib111","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/ATVBAHA.112.300569","article-title":"Galectin-3 mediates aldosterone-induced vascular fibrosis","volume":"33","author":"Calvier","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib112","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.21879","article-title":"Galectin-3 contributes to vascular fibrosis in monocrotaline-induced pulmonary arterial hypertension rat model","volume":"31","author":"Wang","year":"2017","journal-title":"J.\u00a0Biochem. Mol. Toxicol."},{"key":"10.1016\/j.jbc.2022.102622_bib113","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00380-015-0691-z","article-title":"Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension","volume":"31","author":"Fenster","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jbc.2022.102622_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/heartjnl-2015-308365","article-title":"Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension","volume":"102","author":"Calvier","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jbc.2022.102622_bib115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.hlc.2016.12.012","article-title":"Galectin-3 levels are elevated and predictive of mortality in pulmonary hypertension","volume":"26","author":"Mazurek","year":"2017","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.jbc.2022.102622_bib116","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.12659\/MSM.903472","article-title":"Association of serum galectin-3 with the acute exacerbation of chronic obstructive pulmonary disease","volume":"23","author":"Feng","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.jbc.2022.102622_bib117","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/keaa305","article-title":"Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity","volume":"60","author":"Watanabe","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbc.2022.102622_bib118","doi-asserted-by":"crossref","first-page":"103546","DOI":"10.1016\/j.resp.2020.103546","article-title":"Galactin-1, 3 and 9: potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases","volume":"282","author":"d'Alessandro","year":"2020","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.jbc.2022.102622_bib119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF00731303","article-title":"Effects of natural complex carbohydrate (citrus pectin) on murine melanoma cell properties related to galectin-3 functions","volume":"11","author":"Inohara","year":"1994","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.jbc.2022.102622_bib120","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1093\/jnci\/94.24.1854","article-title":"Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin","volume":"94","author":"Nangia-Makker","year":"2002","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.jbc.2022.102622_bib121","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jnci\/84.6.438","article-title":"Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin","volume":"84","author":"Platt","year":"1992","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.jbc.2022.102622_bib122","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3892\/mmr.2016.6020","article-title":"Galectin-3 inhibition ameliorates hypoxia-induced pulmonary artery hypertension","volume":"15","author":"Hao","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.jbc.2022.102622_bib123","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jash.2017.07.009","article-title":"Galectin-3 mediates pulmonary vascular remodeling in hypoxia-induced pulmonary arterial hypertension","volume":"11","author":"Luo","year":"2017","journal-title":"J.\u00a0Am. Soc. Hypertens."},{"key":"10.1016\/j.jbc.2022.102622_bib124","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201711-2308LE","article-title":"Galectin-3 promotes vascular remodeling and contributes to pulmonary hypertension","volume":"197","author":"Barman","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jbc.2022.102622_bib125","doi-asserted-by":"crossref","first-page":"2002559","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jbc.2022.102622_bib126","doi-asserted-by":"crossref","first-page":"e83481","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib127","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jbc.2022.102622_bib128","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jbc.2022.102622_bib129","doi-asserted-by":"crossref","first-page":"H45","DOI":"10.1152\/ajpheart.00609.2018","article-title":"Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling","volume":"316","author":"Nguyen","year":"2019","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.jbc.2022.102622_bib130","doi-asserted-by":"crossref","first-page":"110071","DOI":"10.1016\/j.biopha.2020.110071","article-title":"Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4\/MyD88\/NF-kappaB signaling pathway","volume":"126","author":"Xu","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jbc.2022.102622_bib131","doi-asserted-by":"crossref","first-page":"e0203054","DOI":"10.1371\/journal.pone.0203054","article-title":"Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial","volume":"13","author":"Harrison","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib132","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.matbio.2018.02.004","article-title":"Molecular and tissue alterations of collagens in fibrosis","volume":"68-69","author":"Ricard-Blum","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib133","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1038\/s41598-018-28235-x","article-title":"Crystallization of a human galectin-3 variant with two ordered segments in the shortened N-terminal tail","volume":"8","author":"Flores-Ibarra","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2022.102622_bib134","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/glycob\/cwx071","article-title":"Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization","volume":"27","author":"Miller","year":"2017","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2022.102622_bib135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cei.13379","article-title":"Trypanosoma cruzi cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity","volume":"199","author":"Pineda","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jbc.2022.102622_bib136","doi-asserted-by":"crossref","first-page":"17663","DOI":"10.1074\/jbc.M201562200","article-title":"Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope","volume":"277","author":"Pelletier","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib137","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021074118","article-title":"Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization\/phase separation","volume":"118","author":"Zhao","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102622_bib138","first-page":"3141","article-title":"Molecular basis for MMP9 induction and disruption of epithelial cell-cell contacts by galectin-3","volume":"127","author":"Mauris","year":"2014","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.jbc.2022.102622_bib139","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/glycob\/cwu064","article-title":"Galectin-3 promotes HIV-1 budding via association with Alix and Gag p6","volume":"24","author":"Wang","year":"2014","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2022.102622_bib140","first-page":"457","article-title":"Binding characteristics of galectin-3 fusion proteins","volume":"27","author":"Bocker","year":"2017","journal-title":"Glycobiology"},{"key":"10.1016\/j.jbc.2022.102622_bib141","doi-asserted-by":"crossref","first-page":"e26004","DOI":"10.1371\/journal.pone.0026004","article-title":"LPS-induced galectin-3 oligomerization results in enhancement of neutrophil activation","volume":"6","author":"Fermino","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2022.102622_bib142","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026246118","article-title":"Galectin-3 promotes noncanonical inflammasome activation through intracellular binding to lipopolysaccharide glycans","volume":"118","author":"Lo","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102622_bib143","doi-asserted-by":"crossref","first-page":"24534","DOI":"10.1074\/jbc.M800006200","article-title":"Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site","volume":"283","author":"Kahsai","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib144","doi-asserted-by":"crossref","first-page":"113561","DOI":"10.1016\/j.ejmech.2021.113561","article-title":"Non-carbohydrate strategies to inhibit lectin proteins with special emphasis on galectins","volume":"222","author":"Sethi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib145","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1073\/pnas.93.13.6737","article-title":"Expression of galectin-3 modulates T-cell growth and apoptosis","volume":"93","author":"Yang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2022.102622_bib146","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1158\/0008-5472.CAN-04-0336","article-title":"Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways","volume":"64","author":"Fukumori","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib147","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1042\/bj20031300","article-title":"Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling","volume":"380","author":"Liu","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbc.2022.102622_bib148","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0304-4165(02)00313-6","article-title":"Intracellular functions of galectins","volume":"1572","author":"Liu","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jbc.2022.102622_bib149","doi-asserted-by":"crossref","first-page":"34922","DOI":"10.1074\/jbc.M312697200","article-title":"Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity","volume":"279","author":"Elad-Sfadia","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-4827(03)00211-8","article-title":"Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt","volume":"288","author":"Lee","year":"2003","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jbc.2022.102622_bib151","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1158\/0008-5472.CAN-05-1197","article-title":"Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells","volume":"65","author":"Oka","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib152","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-04-1816","article-title":"Galectin-3, a novel binding partner of beta-catenin","volume":"64","author":"Shimura","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbc.2022.102622_bib153","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/bi00052a033","article-title":"L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity","volume":"32","author":"Massa","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.jbc.2022.102622_bib154","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1016\/S0021-9258(19)50525-7","article-title":"Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin","volume":"267","author":"Sato","year":"1992","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2022.102622_bib155","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1083\/jcb.151.6.1235","article-title":"Induction of terminal differentiation in epithelial cells requires polymerization of hensin by galectin 3","volume":"151","author":"Hikita","year":"2000","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib156","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/(SICI)1097-4644(19991201)75:3<505::AID-JCB14>3.0.CO;2-I","article-title":"Galectin-3 regulates the adhesive interaction between breast carcinoma cells and elastin","volume":"75","author":"Ochieng","year":"1999","journal-title":"J.\u00a0Cell Biochem."},{"key":"10.1016\/j.jbc.2022.102622_bib157","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/bbrc.1998.8708","article-title":"Regulation of cellular adhesion to extracellular matrix proteins by galectin-3","volume":"246","author":"Ochieng","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2022.102622_bib158","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1046\/j.1471-4159.1995.64062465.x","article-title":"Galectin-3, a beta-galactoside-binding animal lectin, binds to neural recognition molecules","volume":"64","author":"Probstmeier","year":"1995","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.jbc.2022.102622_bib159","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1084\/jem.170.6.1959","article-title":"The Mac-2 antigen is a galactose-specific lectin that binds IgE","volume":"170","author":"Cherayil","year":"1989","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jbc.2022.102622_bib160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ncb2970","article-title":"Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers","volume":"16","author":"Lakshminarayan","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jbc.2022.102622_bib161","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1111\/j.1742-4658.2007.05806.x","article-title":"Membrane trafficking of CD98 and its ligand galectin 3 in BeWo cells\u2013implication for placental cell fusion","volume":"274","author":"Dalton","year":"2007","journal-title":"FEBS J."},{"key":"10.1016\/j.jbc.2022.102622_bib162","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pmic.200600482","article-title":"Lipid raft proteome of the human neutrophil azurophil granule","volume":"7","author":"Feuk-Lagerstedt","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.jbc.2022.102622_bib163","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.1102109","article-title":"Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis","volume":"306","author":"Partridge","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jbc.2022.102622_bib164","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1038\/jid.2012.211","article-title":"Galectin-3 regulates intracellular trafficking of EGFR through Alix and promotes keratinocyte migration","volume":"132","author":"Liu","year":"2012","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.jbc.2022.102622_bib165","doi-asserted-by":"crossref","first-page":"14496","DOI":"10.1073\/pnas.0903497106","article-title":"Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822010651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925822010651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:26:56Z","timestamp":1758241616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925822010651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":165,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0021925822010651"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2022.102622","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric galectin-3 and collagens: Biomarkers and potential therapeutic targets in fibroproliferative diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2022.102622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"102622"}}